Gilead Sciences

Gilead Sciences will present HIV research updates at EACS 2025, focusing on person-centered approaches to eradicate the epidemic. Key highlights include: new safety data for twice-yearly lenacapavir as PrEP, strategies to expand PrEP access in Europe, and five-year BICSTaR results demonstrating Biktarvy’s long-term efficacy. The company will also share data on novel long-acting combination regimens, including once-weekly and twice-yearly treatment options, and participant demographics of ARTISTRY-1 study for complex treatment regimens.

Gilead Sciences’ Yeytuo^® (lenacapavir), a twice-yearly injectable HIV-1 capsid inhibitor, has received European Commission (EC) approval for pre-exposure prophylaxis (PrEP). This marks the first and only twice-yearly PrEP option available in the EU, plus Norway, Iceland, and Liechtenstein. Backed by Phase 3 PURPOSE 1 and 2 trial data showing high efficacy, the EC decision follows FDA approval and WHO recommendations. This approval aims to address unmet needs in HIV prevention, particularly among vulnerable populations, and accelerate progress toward ending the HIV epidemic in Europe.